Rezurock (belumosudil) - Romeck Pharma, Sanofi
Jakafi (ruxolitinib) - Incyte
From Flank Pain to Graft-vs.-Host Disease-Related Autoimmune Podocytopathy: A Case of FAT1+ Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0694; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description Our patient underwent an allogeneic HSCT in November 2023 which was complicated by multiorgan chronic GVHD for which he was started on ruxolitinib and belumosudil. While LC-MS/MS identified the antigen target in this case, cohort data show that FAT1+MN can also be identified by immunofluorescence. In FAT1+ MN, IgG subtyping may vary, with IgG4 dominance ranging from the majority of cases to as low as 30%." 
Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Glomerulonephritis • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Nephrology • Pain • CDH23 • FAT1 • NELL1 • PCDH
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4556898
 
Amr Moustafa; Hita S. Moudgalya; Isabelle Ayoub; Alana Dasgupta; Madeline S. Chung; Rima Kang
 
Oct 2, 2026
 
Prev Next